Man Who Predicted Negative Indexes in 2022, Shares "Shocking New Forecast" 
In 20 years, this little-known trader didn't have a single losing year...
Learn more.
Ankit Mahadevia net worth and biography

Ankit Mahadevia Biography and Net Worth

Ankit Mahadevia is the CEO of Spero Therapeutics and a member of the Board of Directors. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, MA. In that capacity he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products including Nimbus Therapeutics, Arteaus Therapeutics (acquired by Lilly), and Translate Bio (Nasdaq: TBIO). He led three of these as Acting CEO, including Synlogic (Nasdaq: SYBX). Prior to joining Atlas in 2008, Ankit worked on product and business development with the founding team at Arcion Therapeutics. He has also held positions in business development both at Genentech and at Vanda Pharmaceuticals. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Ankit began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS). He has spoken widely on entrepreneurship, including at Harvard University, Columbia University, Northwestern University, and the Berkeley Forum. Ankit has also been active in the policy of life science innovation, including service on the Advisory Council at the NIH National Center for Advancing Translational Studies.

How old is Ankit Mahadevia?

Dr. Mahadevia is currently 41 years old. There are 3 older executives and no younger executives at Spero Therapeutics. The oldest executive at Spero Therapeutics is Ms. Tamara Lynn Joseph L.L.M., Chief Legal Officer, who is 59 years old. Learn More on Ankit Mahadevia's age.

How do I contact Ankit Mahadevia?

The corporate mailing address for Dr. Mahadevia and other Spero Therapeutics executives is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. Spero Therapeutics can also be reached via phone at (857) 242-1600 and via email at [email protected] Learn More on Ankit Mahadevia's contact information.

Has Ankit Mahadevia been buying or selling shares of Spero Therapeutics?

Ankit Mahadevia has not been actively trading shares of Spero Therapeutics within the last three months. Most recently, Ankit Mahadevia sold 8,000 shares of the business's stock in a transaction on Monday, December 27th. The shares were sold at an average price of $14.58, for a transaction totalling $116,640.00. Learn More on Ankit Mahadevia's trading history.

Are insiders buying or selling shares of Spero Therapeutics?

During the last year, Spero Therapeutics insiders bought shares 8 times. They purchased a total of 558,224 shares worth more than $7,968,945.93. During the last year, insiders at the sold shares 2 times. They sold a total of 14,017 shares worth more than $121,995.13. The most recent insider tranaction occured on August, 29th when CFO Sath Shukla sold 6,017 shares worth more than $5,355.13. Insiders at Spero Therapeutics own 4.4 % of the company. Learn More about insider trades at Spero Therapeutics.

Information on this page was last updated on 8/29/2022.

Ankit Mahadevia Insider Trading History at Spero Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/27/2021Sell8,000$14.58$116,640.00View SEC Filing Icon  
11/3/2020Sell2,137$14.27$30,494.99View SEC Filing Icon  
10/23/2020Sell20$14.25$285.00View SEC Filing Icon  
10/14/2020Sell105$14.25$1,496.25View SEC Filing Icon  
9/8/2020Sell774$14.25$11,029.50View SEC Filing Icon  
7/9/2020Sell2,293$14.31$32,812.83View SEC Filing Icon  
7/7/2020Sell754$14.25$10,744.50View SEC Filing Icon  
7/6/2018Sell4,676$17.63$82,437.88View SEC Filing Icon  
See Full Table

Ankit Mahadevia Buying and Selling Activity at Spero Therapeutics

This chart shows Ankit Mahadevia's buying and selling at Spero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Spero Therapeutics Company Overview

Spero Therapeutics logo
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.97
Low: $1.92
High: $2.41

50 Day Range

MA: $0.93
Low: $0.68
High: $2.20

2 Week Range

Now: $1.97
Low: $0.68
High: $19.87


41,732,500 shs

Average Volume

2,659,580 shs

Market Capitalization

$69.08 million

P/E Ratio


Dividend Yield



Man Who Predicted Negative Indexes in 2022, Shares "Shocking New Forecast" 
In 20 years, this little-known trader didn't have a single losing year...
Learn more.